Literature DB >> 22770879

Patients' preferences for treatment outcomes of add-on antiepileptic drugs: a conjoint analysis.

Ranjani Manjunath1, Jui-Chen Yang, Alan B Ettinger.   

Abstract

To understand the relative importance of the outcomes of add-on antiepileptic drugs (AEDs) and the willingness of patients with epilepsy to accept therapeutic trade-offs between seizure control and tolerability, we administered a Web-enabled, choice-format conjoint survey to patients with a self-reported physician diagnosis of epilepsy and symptoms of partial seizures. Patients answered nine choice questions to evaluate treatment outcomes of two different hypothetical add-on AEDs. Patients were first asked to choose the better of the two medicines and then asked a follow-up question about whether or not they would add the selected AED to their current treatment regimen. Our study demonstrated that patients with epilepsy consider seizure reduction to be the top priority when ranking it against the reduction or elimination of side effects. This study aids in better understanding of patients' AED treatment preferences and may aid in management of epilepsy.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22770879     DOI: 10.1016/j.yebeh.2012.05.020

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  9 in total

Review 1.  A descriptive review on methods to prioritize outcomes in a health care context.

Authors:  Inger M Janssen; Ansgar Gerhardus; Milly A Schröer-Günther; Fülöp Scheibler
Journal:  Health Expect       Date:  2014-08-25       Impact factor: 3.377

Review 2.  Risk as an attribute in discrete choice experiments: a systematic review of the literature.

Authors:  Mark Harrison; Dan Rigby; Caroline Vass; Terry Flynn; Jordan Louviere; Katherine Payne
Journal:  Patient       Date:  2014       Impact factor: 3.883

3.  Young adult preference analysis on the attributes of COVID-19 vaccine in the Philippines: A conjoint analysis approach.

Authors:  Ardvin Kester S Ong; Yogi Tri Prasetyo; Fae Coleen Lagura; Rochelle Nicole Ramos; Jose Ma Luis Salazar; Keenan Mark Sigua; Jomy Anne Villas; Thanatorn Chuenyindee; Reny Nadlifatin; Satria Fadil Persada; Kriengkrai Thana
Journal:  Public Health Pract (Oxf)       Date:  2022-07-19

Review 4.  Discrete choice experiments in health economics: a review of the literature.

Authors:  Michael D Clark; Domino Determann; Stavros Petrou; Domenico Moro; Esther W de Bekker-Grob
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

5.  Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery.

Authors:  Graham Powell; Emily A F Holmes; Catrin O Plumpton; Adele Ring; Gus A Baker; Ann Jacoby; Munir Pirmohamed; Anthony G Marson; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2015-08-22       Impact factor: 4.335

Review 6.  Sample Size Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide.

Authors:  Esther W de Bekker-Grob; Bas Donkers; Marcel F Jonker; Elly A Stolk
Journal:  Patient       Date:  2015-10       Impact factor: 3.883

7.  Patient Preference for Antiepileptic Drugs Treatment in China: Evidence From the Discrete Choice Experiment.

Authors:  Yingjie Hua; Zhenguo Zhu; Xueying Li; Jiaoni Gong; Siqi Ding; Jiahe Lin; Xinshi Wang; Yanru Du; Niange Xia; Rongyuan Zheng; Huiqin Xu
Journal:  Front Neurol       Date:  2020-12-03       Impact factor: 4.003

Review 8.  Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review.

Authors:  Hiba El Masri; Treasure M McGuire; Mieke L van Driel; Helen Benham; Samantha A Hollingworth
Journal:  Patient Prefer Adherence       Date:  2022-09-20       Impact factor: 2.314

9.  Patient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs.

Authors:  Emily A F Holmes; Catrin Plumpton; Gus A Baker; Ann Jacoby; Adele Ring; Paula Williamson; Anthony Marson; Dyfrig A Hughes
Journal:  Clin Pharmacol Ther       Date:  2018-10-25       Impact factor: 6.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.